Drug Development
Design of beta3 -AR agonists for obesity, diabetes, and urination therapies are reviewed
Published in Obesity and Diabetes Week, February 13th, 2006
According to a recent review from Japan, "The beta3 -adrenergic receptor (beta3 -AR) has been shown to mediate various pharmacological and physiological effects such as lipolysis, thermogenesis, and relaxation of the urinary bladder. Activation of the beta(3)-AR is thought to be a possible approach for the treatment of obesity, type 2 diabetes mellitus, and frequent urination."
"Therefore, the beta3 -AR is recognized as an attractive target for drug...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Pathogenesis
Improved insulin resistance after weight loss is not linked to adiponectin changes - Diet & Nutrition
Long-chain polyunsaturated fatty acid diet may protect obese against metabolic syndrome - Drug Safety
Orlistat and micronized fenofibrate are safe and effective for overweight and obese - Obesity Therapy
(+)-Z-BDDA may have applications in treating obesity and metabolic syndrome complications - Type 2 Diabetes
Vaspin expression in adipose tissue may be linked to obesity and type 2 diabetes - Anesthesia
Anesthesia can cause sustained hyperglycemia in C57/BL6J mice - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
